Pharmacological boosting of HSP levels, by inhibition of the RhoA pathway and enhancing binding of HSF1 to HSP genes, in atrial tissue may aid in the accelerated recovery from cardiomyocyte damage and, as such, may result in halting of AF. The gene discussed is HSP90B2P; the disease is atrial fibrillation.